Announcements Trials
Browse Landscape

Phase

Phase 1/2 3Phase 2 2Phase 3 1

Status

Recruiting 2Terminated 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 2

Conditions

Carcinoma, Non-Small-Cell Lung 114Breast Neoplasms 79Neoplasms 74Neoplasm Metastasis 63Colorectal Neoplasms 62Prostatic Neoplasms 57Recurrence 56Pancreatic Neoplasms 55Leukemia, Myeloid, Acute 55Ovarian Neoplasms 53Multiple Myeloma 50Melanoma 39Glioblastoma 38Squamous Cell Carcinoma of Head and Neck 33Lung Neoplasms 33Triple Negative Breast Neoplasms 31Lymphoma, Non-Hodgkin 30Endometrial Neoplasms 30Precursor Cell Lymphoblastic Leukemia-Lymphoma 29Lymphoma 27Carcinoma, Renal Cell 27Lymphoma, Large B-Cell, Diffuse 26Stomach Neoplasms 25Lymphoma, B-Cell 25Carcinoma, Hepatocellular 24Advanced Solid Tumor 24Small Cell Lung Carcinoma 23Leukemia, Lymphocytic, Chronic, B-Cell 23Burkitt Lymphoma 23Brain Neoplasms 23

Interventions

enzalutamide 1darolutamide 1abiraterone 1AZD5305 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × Bulbo-Spinal Atrophy, X-Linked × 90 days × Clear all
NCT07190300 2026-06-03

TulmiSTAR-02

Novartis

Phase 1/2 Recruiting
181 enrolled

Bulbo-Spinal Atrophy, X-Linked

NCT03437941 2026-05-15

Study to Evaluate Exicorilant (CORT125281) in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer

Corcept Therapeutics

Phase 1/2 Terminated
39 enrolled 43 charts
Genitourinary

Prostatic Neoplasms, Bulbo-Spinal Atrophy, X-Linked

NCT07336446 2026-05-01

ANDROMEDA

AstraZeneca

Phase 1/2 Recruiting
300 enrolled
Genitourinary

Prostatic Neoplasms, Bulbo-Spinal Atrophy, X-Linked

Data powered by HemOnc (CC BY 4.0) Colophon âš¡